{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:28:41Z","timestamp":1791919721662,"version":"4.3.4"},"reference-count":110,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.2217\/fon-2019-0468","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T10:48:17Z","timestamp":1576147697000},"page":"4439-4453","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":32,"title":["Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer"],"prefix":"10.1080","volume":"16","author":[{"given":"Athanasios","family":"Mavratzas","sequence":"first","affiliation":[{"name":"National Center for Tumor Disease,Gynecologic Oncology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Seitz","sequence":"additional","affiliation":[{"name":"National Center for Tumor Disease,Gynecologic Oncology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Smetanay","sequence":"additional","affiliation":[{"name":"National Center for Tumor Disease,Gynecologic Oncology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schneeweiss","sequence":"additional","affiliation":[{"name":"National Center for Tumor Disease,Gynecologic Oncology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"J\u00e4ger","sequence":"additional","affiliation":[{"name":"National Center for Tumor Disease,Gynecologic Oncology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Fremd","sequence":"additional","affiliation":[{"name":"National Center for Tumor Disease,Gynecologic Oncology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,12,12]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-015-3564-3"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S69488"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-007-9632-6"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27581"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.03.015"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy201"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt276"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-0887-0285"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60070-6"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.1255"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2560"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2018.1458613"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djg050"},{"issue":"5","key":"e_1_3_4_17_1","first-page":"1206","article-title":"Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer","volume":"60","author":"Lidereau R","year":"2000","unstructured":"Lidereau R , EisingerF, ChampemeMHet al. Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer. Cancer Res.60(5), 1206\u20131210 (2000).","journal-title":"Cancer Res."},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802905"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1711644"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz012"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0432"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0550-y"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157368"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1061"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05220-6"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30904-X"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.55.0491"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.4161\/onci.24720"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2702"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3944"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2013.03.010"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy399"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2012.04657.x"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/70932"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-2988-5"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5583"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2015.09.006"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-017-0781-0"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06653-9"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2018.05.006"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000061"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003689"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-004-0593-x"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm730"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80089-8"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.26.021607.090331"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0367"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1136043"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14011"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2009.112"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2007.10.156"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature13904"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-016-0371-6"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.2165\/11596370-000000000-00000"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.4224"},{"key":"e_1_3_4_58_1","first-page":"77","article-title":"Atezolizumab in metastatic TNBC (mTNBC): long-term clinical outcomes and biomarker analyses. Proceedings of the American Association for Cancer Research Annual Meeting 2017 Apr 1\u20135; Washington, DC. Philadelphia (PA): AACR","volume":"2017","author":"Schmid PC","year":"2017","unstructured":"Schmid PC , BraitehFS, EderJPet al. Atezolizumab in metastatic TNBC (mTNBC): long-term clinical outcomes and biomarker analyses. Proceedings of the American Association for Cancer Research Annual Meeting 2017 Apr 1\u20135; Washington, DC. Philadelphia (PA): AACR. Cancer Res.2017, 77 (2017).","journal-title":"Cancer Res."},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4537-5"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8931"},{"key":"e_1_3_4_61_1","first-page":"78","article-title":"KEYNOTE-086 cohort B: pembrolizumab monotherapy for PD-L1\u2013positive, previously untreated, metastatic triple-negative breast cancer (mTNBC) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5\u20139; San Antonio, TX. Philadelphia (PA): AACR","volume":"2018","author":"Adams SL","year":"2018","unstructured":"Adams SL , ToppmeyerDL, CesconDWet al. KEYNOTE-086 cohort B: pembrolizumab monotherapy for PD-L1\u2013positive, previously untreated, metastatic triple-negative breast cancer (mTNBC) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5\u20139; San Antonio, TX. Philadelphia (PA): AACR. Cancer Res.2018, 78 (2018).","journal-title":"Cancer Res."},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy517"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy518"},{"key":"e_1_3_4_64_1","first-page":"34","article-title":"KEYNOTE-119: A randomized Phase III study of single-agent pembrolizumab (MK-3475) vs single-agent chemotherapy per physician's choice for metastatic triple-negative breast cancer (mTNBC)","volume":"34","author":"Winer E","year":"2017","unstructured":"Winer E , DangT, KarantzaV, SuSC. KEYNOTE-119: A randomized Phase III study of single-agent pembrolizumab (MK-3475) vs single-agent chemotherapy per physician's choice for metastatic triple-negative breast cancer (mTNBC). J. Clin. Oncol.34, 34 (2017).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_4_65_1","unstructured":"Merck . Update on Phase III KEYNOTE-119 study of KEYTRUDA\u00ae (pembrolizumab) monotherapy in previously-treated patients with metastatic triple-negative breast cancer (2019). https:\/\/bit.ly\/2WYCRjO"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.10.012"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-1016-03"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0895"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1298"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1545"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5152"},{"key":"e_1_3_4_72_1","first-page":"Abstract nr OT3","article-title":"Phase Ib\/II study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer. Proceedings of the 2016 San Antonio Breast Cancer Symposium. AACR, San Antonio, TX, USA, 6\u201310 December 2016","volume":"77","author":"Tolaney S","year":"2017","unstructured":"Tolaney S , SavulskyC, AktanG, XingD, KarantzaV, DiabS. Phase Ib\/II study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer. Proceedings of the 2016 San Antonio Breast Cancer Symposium. AACR, San Antonio, TX, USA, 6\u201310 December 2016. Cancer Res.77, Abstract nr OT3-04-05 (2017).","journal-title":"Cancer Res."},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0520-5"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3215"},{"key":"e_1_3_4_75_1","article-title":"Evaluation of niraparib in combination with anti-PD1\/anti-PD-L1 in preclinical models. Proceedings of the American Association for Cancer Research Annual Meeting 2018. AACR, Chicago, IL, USA, 14\u201318 April 2018","volume":"78","author":"Wang S","year":"2018","unstructured":"Wang S , SunK, XiaoYet al. Evaluation of niraparib in combination with anti-PD1\/anti-PD-L1 in preclinical models. Proceedings of the American Association for Cancer Research Annual Meeting 2018. AACR, Chicago, IL, USA, 14\u201318 April 2018. Cancer Res.78 (2018).","journal-title":"Cancer Res."},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1029"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1340"},{"key":"e_1_3_4_78_1","first-page":"78","article-title":"An open-label, multitumor, Phase II basket study of olaparib and durvalumab (MEDIOLA): results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC). Proceedings of the 2017 San Antonio Breast Cancer Symposium. AACR, San Antonio, TX, USA, 5\u20139 December 2017","volume":"2018","author":"Domchek S","year":"2018","unstructured":"Domchek S , BangYJ, ParkYHet al. An open-label, multitumor, Phase II basket study of olaparib and durvalumab (MEDIOLA): results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC). Proceedings of the 2017 San Antonio Breast Cancer Symposium. AACR, San Antonio, TX, USA, 5\u20139 December 2017. Cancer Res.2018, 78 (2018).","journal-title":"Cancer Res."},{"key":"e_1_3_4_79_1","first-page":"78","article-title":"The DORA trial: a non-comparator randomised Phase II multi-center maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum treated advanced triple negative breast cancer (TNBC). Proceedings of the 2017 San Antonio Breast Cancer Symposium. AACR, San Antonio, TX, USA, 5\u20139 December 2017","volume":"2018","author":"Dent R","year":"2018","unstructured":"Dent R , KimSB, TrainaTet al. The DORA trial: a non-comparator randomised Phase II multi-center maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum treated advanced triple negative breast cancer (TNBC). Proceedings of the 2017 San Antonio Breast Cancer Symposium. AACR, San Antonio, TX, USA, 5\u20139 December 2017. Cancer Res.2018, 78 (2018).","journal-title":"Cancer Res."},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.1003"},{"key":"e_1_3_4_82_1","doi-asserted-by":"crossref","unstructured":"Emens LA RugoHS SchneeweissAet al. IMpassion130: efficacy in immune biomarker subgroups from the global randomized double-blind placebo-controlled Phase III study of atezolizumab + nab-paclitaxel in patients with treatment-na\u00efve locally advanced or metastatic triple-negative breast cancer. Presented at: SABCS. Abstract GS01-04 San Antonio TX USA 4\u20138 December 2018.","DOI":"10.1158\/1538-7445.SABCS18-GS1-04"},{"issue":"5","key":"e_1_3_4_83_1","first-page":"v851","article-title":"Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): post-hoc analysis of Impassion130","volume":"30","author":"Rugo HS","year":"2019","unstructured":"Rugo HS , AdamsS, SchmidPet al. Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): post-hoc analysis of Impassion130. Ann. Oncol.30(Suppl. 5), v851\u2013v934 (2019).","journal-title":"Ann. Oncol."},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.03.052"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv383"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13063"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2013.33.e280"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00108"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130790"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13746"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0013-y"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0461-4"},{"issue":"1","key":"e_1_3_4_96_1","doi-asserted-by":"crossref","first-page":"e000278","DOI":"10.1136\/esmoopen-2017-000278","article-title":"Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management","volume":"3","author":"Geukes Foppen MH","year":"2018","unstructured":"Geukes Foppen MH , RozemanEA, van WilpeSet al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open3(1), e000278 (2018).","journal-title":"ESMO Open"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00005"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2016.10.002"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008002"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13028"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.06.002"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1111\/cup.12858"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.02.035"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx642"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2005"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2736"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30483-8"},{"issue":"5","key":"e_1_3_4_109_1","first-page":"v851","article-title":"KEYNOTE-522: Phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab versus placebo as adjuvant treatment for early triple-negative breast cancer (TNBC)","volume":"30","author":"Schmid PC","year":"2019","unstructured":"Schmid PC , DentR, PusztaiLet al. KEYNOTE-522: Phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab versus placebo as adjuvant treatment for early triple-negative breast cancer (TNBC). Ann. Oncol.30(Suppl. 5), v851\u2013v934 (2019).","journal-title":"Ann. Oncol."},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30026-9"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2019.1537785"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11050628"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2019-0468","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:45:53Z","timestamp":1719125153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2019-0468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,12]]},"references-count":110,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.2217\/fon-2019-0468"],"URL":"https:\/\/doi.org\/10.2217\/fon-2019-0468","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-08-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}